A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
Status:
Completed
Trial end date:
2019-11-22
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the safety of THR-317 when administered intravitreally
and to assess the compound's efficacy in reducing central subfield thickness (CST) and
improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1
(MacTel 1).